The actual restenosis complaint rate (0.04%) was higher than the predicted FMEA rate of 0.01% due to inclusion of complaints from the BOLSTER trial. The purpose of the recall is to advise users of the restenosis rate and provide an update to the Instructions for Use (IFU) for the LifeStream Balloon Expandable Vascular Covered Stent to include BOLSTER clinical trial results.